Skip to main content
. 2013 Oct 3;13:458. doi: 10.1186/1471-2334-13-458

Table 3.

Distribution of outcomes after discontinuation of lamivudine, adefovir, entecavir, and telbivudine

NUCs Sustained response - no. (%) Relapse - no. (%)
LAM
11 (24.4)
2 (10.5)
ADV
27 (60.0)
15 (78.9)
ETV
5 (11.1)
2 (10.5)
LDT 2 (4.4) 0

LAM, lamivudine; ADV, adefovir; ETV, entecavir; LDT, telbivudine.